NCT06086522PHASE1Recruiting

Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

Qualigen Theraputics, Inc.

Start Date

11/1/2023

Completion Date

12/1/2026

Summary

Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patient.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Patients with histologically confirmed locally advanced or metastatic solid carcinomas, who have had tumor progression after receiving all standard of care therapies or for which there is no approved therapy 2. Evaluable or measurable disease by RECIST 1.1 Exclusion Criteria: \-

Interventions

DRUG

QN-302

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Solid Tumor

Locations

HonorHealth

Scottsdale, Arizona 85251

United States

Yale

New Haven, Connecticut 06520

United States

START Midwest

Grand Rapids, Michigan 49546

United States

MD Anderson Cancer Center

Houston, Texas 77002

United States